


## BQ-123 TFA

Cat. No.:	HY-12378A
Molecular Formula:	C <sub>33</sub> H <sub>43</sub> F <sub>3</sub> N <sub>6</sub> O <sub>9</sub>
Molecular Weight:	724.72
Target:	Endothelin Receptor
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	BQ-123 TFA is a potent and selective endothelin A (ETA) receptor antagonist with an IC <sub>50</sub> of 7.3 nM and a K <sub>i</sub> of 25 nM. BQ-123 TFA inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells and lowers blood pressure in different rat models of hypertension <sup>[1][2][3]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 7.3 nM (Endothelin A receptors) <sup>[1]</sup> K <sub>i</sub> : 25 nM (Endothelin A receptors) <sup>[2]</sup>								
<b>In Vivo</b>	<p>Sustained infusions of BQ-123 (0.16-164 nmol/kg per min, intravenously, for 6 h) produces dose-dependent reductions in mean arterial pressure in spontaneously hypertensive rats (SHR), the maximal reduction being obtained with a dose of 16 nmol/kg per min<sup>[4]</sup>.</p> <p>BQ-123 (3 mg/kg; i.v.; given 15 minutes before pentylenetetrazole (PTZ)) impedes the formation and spread of seizure to a great degree in PTZ (50 mg/kg; i.p.) +BQ-123 groups<sup>[5]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male Wistar albino rats<sup>[5]</sup></td> </tr> <tr> <td>Dosage:</td> <td>3 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection; given 15 minutes before PTZ</td> </tr> <tr> <td>Result:</td> <td>Number of rats with major seizure decreased.</td> </tr> </table>	Animal Model:	Male Wistar albino rats <sup>[5]</sup>	Dosage:	3 mg/kg	Administration:	Intravenous injection; given 15 minutes before PTZ	Result:	Number of rats with major seizure decreased.
Animal Model:	Male Wistar albino rats <sup>[5]</sup>								
Dosage:	3 mg/kg								
Administration:	Intravenous injection; given 15 minutes before PTZ								
Result:	Number of rats with major seizure decreased.								

### CUSTOMER VALIDATION

- PLoS Pathog. 2020 Oct 19;16(10):e1008947.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

### REFERENCES

- 
- [1]. Ihara M, et al. In vitro biological profile of a highly potent novel endothelin (ET) antagonist BQ-123 selective for the ETA receptor. J Cardiovasc Pharmacol. 1992;20 Suppl 12:S11-S14.
- [2]. Sakamoto A, et al. Distinct subdomains of human endothelin receptors determine their selectivity to endothelinA-selective antagonist and endothelinB-selective agonists. J Biol Chem. 1993 Apr 25;268(12):8547-53.
- [3]. Zamora MA, et al. BQ123, an ETA receptor antagonist, inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol. 1993;9(4):429-433.
- [4]. Douglas SA, et al. BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension. J Hypertens. 1994;12(5):561-567.
- [5]. Erdogan H et al. The protective effects of endothelin-A receptor antagonist BQ-123 in pentylenetetrazole-induced seizure in rats. Hum Exp Toxicol, 2014 Oct, 33(10):1008-16.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA